Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.560
+0.010 (0.65%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Employees
As of December 31, 2025, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees did not change compared to the previous year.
Employees
77
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$189,039
Profits / Employee
-$825,104
Market Cap
388.58M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Invivyd | 122 |
| Enanta Pharmaceuticals | 120 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 96 |
LCTX News
- 15 days ago - Lineage Announces Formation of Scientific Advisory Board - Business Wire
- 5 weeks ago - Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease - Business Wire
- 7 weeks ago - Lineage Cell Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Business Wire
- 4 months ago - Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
- 4 months ago - Lineage Cell Therapeutics Issues Letter to Stockholders - Business Wire
- 6 months ago - Lineage Cell Therapeutics Earnings Call Transcript: Q3 2025 - Transcripts